Last reviewed 2026-04-20 · How we verify

Spironolacton

At a glance

Approved indications

• Aldosteronism
• Ascites
• Chronic heart failure
• Diagnostic Test for Primary Aldosteronism
• Edema
• Edema due to Hepatic Cirrhosis
• Edema due to Nephrotic Syndrome
• Hypertensive disorder
• Hypokalemia Prevention
• Peripheral Edema due to Chronic Heart Failure
• Pulmonary Edema due to Chronic Heart Failure

Common side effects

• Gynecomastia
• Hyperkalemia
• Nausea
• Diarrhea
• Vomiting
• Headache
• Dizziness
• Leg cramps
• Drowsiness
• Lethargy
• Irregular menses or amenorrhea
• Decreased libido

Serious adverse events

• Stevens-Johnson Syndrome (SJS)
• Toxic epidermal necrolysis (TEN)
• Anaphylactic reactions
• Renal failure
• Hepatocellular toxicity
• Agranulocytosis
• Thrombocytopenia
• Gastric bleeding
• Vasculitis
• Drug rash with eosinophilia and systemic symptoms (DRESS)

Key clinical trials

• OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure (PHASE2)
• The Role of Skin Sodium Accumulation in Chronic Kidney Disease (NA)
• Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure (PHASE2)
• A Crossover Study With Hexalacton in Patients With Type 1 Diabetes and Microalbuminuria (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Spironolacton CI brief — competitive landscape report
• Spironolacton updates RSS · CI watch RSS
• ACS Biomarker portfolio CI